Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations sending the company’s stock price spiralling. Despite ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Bagsværd, Denmark, 20 December 2024– Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68- week efficacy and ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new late-stage results for CagriSema.

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Stream Los Angeles News ...